• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Investors Are Reacting To Zebra Technologies (ZBRA) Expanding AI‑Ready Bedside Devices At University Health

    Simply Wall St·09/03/2026 00:39:51
    语音播报
    • In early September 2026, University Health disclosed that it had rolled out Zebra Technologies’ TC5, HC2X/HC5X mobile computers and ZQ600 Plus mobile printers to more than 90% of its frontline inpatient staff to streamline bedside workflows and reduce communication bottlenecks.
    • This deployment shows how Zebra’s healthcare‑focused devices and EHR integration can turn bedside data into real-time clinical insights, including AI-ready workflows in medication management, neonatal care, and wound documentation.
    • We’ll now examine how this large-scale, EHR-integrated bedside deployment could influence Zebra’s investment narrative around automation and workflow optimization.

    AI is about to change healthcare. These 38 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

    Zebra Technologies Investment Narrative Recap

    To own Zebra Technologies, you need to believe its core advantage lies in automating frontline work and turning real‑time data into better decisions across hospitals, warehouses, and stores. The University Health rollout reinforces this automation and workflow thesis in healthcare, but it does not materially change the near term catalyst, which still centers on executing double digit 2026 sales growth, or the key risk that hardware driven revenue leaves earnings more exposed to macro and sector slowdowns.

    The University Health deployment lines up closely with Zebra’s Orchestrated Care framework announced in March 2026, which highlighted AI enabled bedside workflows and healthcare specific hardware. Together, they show how Zebra is trying to deepen its role in mission critical clinical workflows while building a richer software and data layer on top of its devices, a direction that could matter for the long term push toward more recurring, services oriented revenue if execution continues.

    Yet beneath these operational wins, investors still need to consider how exposed Zebra remains if demand softens and its shift beyond hardware does not progress as planned...

    Read the full narrative on Zebra Technologies (it's free!)

    Zebra Technologies’ narrative projects $7.2 billion revenue and $991.3 million earnings by 2029. This requires 7.0% yearly revenue growth and a roughly $452 million earnings increase from $539.0 million today.

    Uncover how Zebra Technologies' forecasts yield a $399.00 fair value, a 14% upside to its current price.

    Exploring Other Perspectives

    ZBRA 1-Year Stock Price Chart
    ZBRA 1-Year Stock Price Chart

    Some of the most cautious analysts expected Zebra’s revenue to reach about US$6.7 billion and earnings near US$703 million by 2029, yet they still worried that tariff costs and slower manufacturing demand could cap valuation multiples. The University Health news could eventually influence both views, but it also shows how differently you might weigh the same risks and opportunities compared with the most pessimistic forecasts.

    Explore 5 other fair value estimates on Zebra Technologies - why the stock might be worth 17% less than the current price!

    Form Your Own Verdict

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Contemplating Other Strategies?

    The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.